{"id":"W1484884408","doi":"10.1200/jco.2012.30.15_suppl.6505","title":"Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Discontinuation; Internal medicine; Imatinib mesylate; Myeloid leukemia; Clinical endpoint; Oncology; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001071167,0.0004266628,0.00113964,0.0002369687,0.0001738534,0.0005807066,0.0004323693,0.0006223387,0.002841534],"category_scores_gemma":[0.0009822409,0.0001761536,0.0008699044,0.0002349415,0.0003304601,0.0006147033,0.0003104379,0.001330925,0.0003525979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006419965,"about_ca_system_score_gemma":0.0004377592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005468428,"about_ca_topic_score_gemma":0.002341234,"domain_scores_codex":[0.9996086,0.000160465,0.00003482734,0.00007838806,0.00003444225,0.00008338209],"domain_scores_gemma":[0.9993677,0.0002107883,0.0001284961,0.00003826868,0.00001693304,0.0002378566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8815394,0.008953967,0.01281343,0.0003552588,0.0007063699,0.0001549088,0.0001563352,0.001067927,0.006794516,0.0001170006,0.0008712765,0.08646961],"study_design_scores_gemma":[0.1980724,0.6915485,0.09838247,0.0001209174,0.001205937,0.0004421967,0.0001948019,0.002688461,0.003742993,0.0004017329,0.003149612,0.00005000846],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977313,0.001064612,0.00008024735,0.000107521,0.0000484751,0.0001542399,0.000168408,0.0000144477,0.000630734],"genre_scores_gemma":[0.9983798,0.0004081718,0.0001430671,0.0001393979,0.00004930822,0.000121576,0.0002790657,0.000002908573,0.0004767124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002841534,"threshold_uncertainty_score":0.009505868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05594910151100691,"score_gpt":0.3982784705581594,"score_spread":0.3423293690471525,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}